LWMI
SUPN icon

Legacy Wealth Management (Idaho)’s Supernus Pharmaceuticals SUPN Stock Holding History

Legacy Wealth Management (Idaho)’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-27
Closed -$1.4K – 866
2026
Q1 		$1.4K Sell
27
-16
-37% -$815 ﹤0.01% 828
2025
Q4 		$2.14K Buy
43
+35
+438% +$1.7K ﹤0.01% 660
2025
Q3 		$383 Hold
8
– – ﹤0.01% 700
2025
Q2 		$253 Hold
8
– – ﹤0.01% 695
2025
Q1 		$262 Hold
8
– – ﹤0.01% 751
2024
Q4 		$308 Hold
8
– – ﹤0.01% 696
2024
Q3 		$303 Buy
+8
New +$250 ﹤0.01% 646

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Legacy Wealth Management (Idaho)'s SUPN Position: Q2 2026 in Review

Legacy Wealth Management (Idaho) sold out of Supernus Pharmaceuticals (SUPN) in Q2 2026, closing a stake of 27 shares — an estimated $1.4K sold.

Legacy Wealth Management (Idaho) first reported a position in SUPN in Q3 2024 and held it in 7 quarters. The position peaked at $2.14K in Q4 2025. 332 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Legacy Wealth Management (Idaho) reported no remaining Supernus Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Legacy Wealth Management (Idaho) sold 27 Supernus Pharmaceuticals shares in Q2 2026, an estimated $1.4K.
  • Legacy Wealth Management (Idaho) first reported a position in Supernus Pharmaceuticals in Q3 2024 and held it in 7 quarters.
  • Legacy Wealth Management (Idaho)'s Supernus Pharmaceuticals position peaked at $2.14K in Q4 2025.
  • 332 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Legacy Wealth Management (Idaho)'s 13F filing for Q2 2026, filed 13 Aug 2026.